Asp Isotopes Inc. · NASDAQ:ASPI
Asp Isotopes — Investor Presentation (June 2023)
30 slides from Asp Isotopes's investor presentation, Jun 12, 2023
Slide 1: Corporate Overview June 2023
ASP isotopes Corporate Overview June 2023
Slide 2: Forward Looking Statements
Forward Looking Statements ‘This presentation contains “forward-looking statements". Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, f
Slide 3: ASP Isotopes: At a Glance
ASP Isotopes: At a Glance B 1. Proven & Proprietary Technology ASPI's advanced technology platform leverages 20 years of R&D history to enrich isotopes in varying levels of atomic mass. Its innovative technology will enable the company to manufacture a diverse range of isotopes, which will meet the
Slide 4: ASP Isotopes: Technology Highlights
ASP Isotopes: Technology Highlights A 1. Cost-Effective Ce J Isotope enrichment facilities using ASP technology can be constructed at a fraction of capital cost and time vs. traditional isotope separation facilities. This technology has been refined for over 20 years through the South African Nuclea
Slide 5: ASP Isotopes: Macro Highlights
ASP Isotopes: Macro Highlights 1. Geopolitical Tailwinds Recent geopolitical events have made governments and companies worldwide reassess their reliance on Russia to produce isotopes. Russia's production share of the global medical isotope market is 22%, and China and Russia together comprised 57%
Slide 6: Company History
Company History October 2021 ‘ July 2022 {ASP islopes wins competive auction fr March 2023 December 2020 "yon Large sale Pra and Acquistion ofthe Small Seale a lGhodkkin ad Feed aoa $6 ion Plant enichment fact from ots Small Sale Plant * . 2021 2022 22s . . . ° September 2021 Jan/Feb 2022 November 2
Slide 7: Anticipated Milestones
Anticipated Milestones MARKET MILESTONES 1. Secure at least 2 more supply agreements for isotopes critical for new technologies and healtheare. 2. Generate sufficient revenues for the company to have annual positive operating cash flow. 3. Enter additional supply contracts for new isotopes in the 20
Slide 8: ASP Isotopes Leadership Team
ASP Isotopes Leadership Team PAUL MANN Chairman, and CEO Co-founded ASP Isotopes in September 2021 20+ years of experience on Wall Street investing in healthcare and chemicals companies at Soros Fund Management, Highbridge Capital and Morgan Stanley. MA and MEng (Chemical Engineering) from Cambridge
Slide 9: What Is An Isotope?
What Is An Isotope? Isotopes are like identical twins or triplets: very similar in most aspects, except for a few subtle differences. + Isotopes are two or more atoms of the same chemical element with the same number of protons and electrons but slightly different numbers of neutrons. + Isotopes are
Slide 10: Isotopes of Interest
Isotopes of Interest Under Commercially Isotopes End-Market R&D Stage R&D Evaluation Construction Available Carbon-14 Pharma & gocher Silicon-28 Quantum Computing — eee iE Germanium-70/72/74 Quantum Computing > Molybdenum-100 ak Nuclear Medicine ‘Molybdenum-98. — Zinc- 67/68 Ytterbium-176 Nuclear Me
Slide 11: ASP Technology Creates Stable Isotopes More Efficiently
ASP Technology Creates Stable Isotopes More Efficiently TRADITIONAL TECHNOLOGY Expensive and Capital intensive Traditionally, isotopes have been separated using a gas centrifuge, in which a cylinder spins extremely quickly. Thus, centrifugal forces allow heavier isotopes to get separated from lighte
Slide 12: ASP Technology: Stationary Wall Centrifuge
ASP Technology: Stationary Wall Centrifuge Benefits of a Stationary Wall Centrifuge No moving parts vs. a conventional centrifuge No unique materials are required Cost-efficient at small scale > PON High Separation Efficiency = Small Production ««====— Flexible Capacity Ce] Modules Deployment High S
Slide 13: Isotope End Markets: Nuclear Medicine
Isotope End Markets: Nuclear Medicine ISOTOPES OF INTEREST END MARKET Carbon-Dating PET Scan imaging Oncology Oncology SPECT Scan Treatment Treatment Pharmacokinetic Imaging Oncology (Non-Hodgkin (Neuroendocrine Tracing Treatment fmenome, Frostaie ‘Tumors NETs) Cancer, NETS) ASP isotopes in ASP isot
Slide 14: Isotope End Markets: Carbon-14 (14C)
Isotope End Markets: Carbon-14 (14C) Radiolabeling scientific technique used to track the passage of a molecule. The technique incorporates a radioisotope through a reaction, cell, organism, biological system, or metabolic pathway. Carbon-14 Used as a radiolabeling compound due to its’ relatively ha
Slide 15: Isotope End Markets: Molybdenum-100 and Zinc-68
Isotope End Markets: Molybdenum-100 and Zinc-68 Imaging Agent Distribution Single-photon emission 2 computed tomography (SPECT) = It is estimated that 80-85% of all Technetium-99 SPECT procedures utilize ~ Sizes ‘Technetium-99° Soba vai See °°T¢ Global Market Size $4.61B $4.17B Imaging Agent Distrib
Slide 16: Nuclear Medicine Supply Chain
Nuclear Medicine Supply Chain Current Isotope Conversion Process Reactor Target Irradiation Current Mo99 Supply Chain Purified Mo-99/Te-99m Mo-99 Generators 7 Generator Manufacturer Hospitals, Pharmacies ASP Isotope Conversion Process 99Mlo => 9To Half-Life: 66 Hours Half-Life: 6 Hours 100110 o> [Te
Slide 17: Geopolitical Tailwinds for ASPI Nuclear Medicine
Geopolitical Tailwinds for ASPI Nuclear Medicine World's Largest Nuclear Facilities Manufacturing Isotopes 1. Government Support for Alternative Supply “Between 95 and 98 percent of 2°Mo is currently being produced using highly enriched uranium (HEU) targets, which was the major concern of Congress.
Slide 18: Isotopes End-Markets: Green Nuclear Energy
Isotopes End-Markets: Green Nuclear Energy Nuclear Power provides ~10% of global electricity generation’ NUCLEAR FUEL SOURCES | HIGH ASSAY LOW ENRICHED URANIUM LOW-ENRICHED URANIUM HALEU (15-19.75%) LEU (5%) To reach Net Zero emissions by 2050, the World Must: £52) In 2021 nuclear power eapacty fT d
Slide 19: Leveraging ASP Technology in Green Nuclear Energy
Leveraging ASP Technology in Green Nuclear Energy OUR SOLUTION 1. Enrich LEU (5.0%) + ASP isotopes mmm) HALEU (15-19.75%) @ Our Process produces waste with Uranium-235 content at 0.71%. Equivalent to naturally occurring uranium NEXT STEPS —> 2. Conduct Bench Tests 2emonsttate the ertectiveness of AS
Slide 20: Geopolitical Tailwinds for ASPI Green Nuclear Energy
Geopolitical Tailwinds for ASPI Green Nuclear Energy 9 Energy Security = Russia is responsible for 35% of enriched uranium globally’ = The United States imports 95% of its uranium and 81% of its enrichment ‘comes from overseas. '© 8 Increasing Focus on Nuclear Power By Country UK plans to build 8 ne
Slide 21: Market Opportunities of Other Isotopes
Market Opportunities of Other Isotopes For Use in Quantum Computing 1. Quantum computing requires ultra-pure Silicon-28 Which is not available at any price at commercial scale 2. ASP Intends to conduct further testing to enhance the current capability of enrichment of Si28 up to. commercial requirem
Slide 22: Investment Thesis
Investment Thesis ER 1. Proven & Proprietary Technology ASPI's advanced technology platform leverages 20 years of R&D history to enrich isotopes in varying levels of atomic mass. Its innovative technology will enable the company to manufacture a diverse range of isotopes, which will meet the growing
Slide 23: Supplemental Background Information
Supplemental Background Information (©AS? isotopes le ASP isotopes»
Slide 24: Isotope status by element (periodic table)
infinal stages of ANI and Zn = active 4 Li| Be ‘ito and™Mo= pan ome ; construction consideration Mg (23\>- ~ 4 fbst—2yp@e as ASP isotopes ~
Slide 25: Advantages of ASP vs. Competing Technologies
Advantages of ASP vs. Competing Technologies Energy Used for Energy Process ‘Separation Mechanism z intensity kwh CAPeX Cost + ASPI has a robust, versatile platform of oh - is Differential Diffusion isotope enrichment technologies — fag canons fone io thie ourent Diffusion ee Mechanical 2,500 High p
Slide 26: Technetium-99m Production Pathways
Tcechnetium-99m Production Pathways = Te can be produced using "Mo or» "Mo and °°Mpo are stable and do not undergo radioactive decay; they can "Mo either directly or indirectly therefore be shipped and stored like traditional products, removing many supply chain issues associated with the current me
Slide 27: Silicon-28: Enabling Quantum Computing
Silicon-28: Enabling Quantum Computing Quantum Computers are expected to be 1000x more powerful than today's conventional computers, and widely anticipated that they will create new opportunities in medicine, artificial intelligence, cybersecurity, finance, logistics, and other industries. For the p
Slide 28: SMR (Small Modular Reactors) - Next Wave in Nuclear Energy
SMR (Small Modular Reactors) = Next Wave in Nuclear Energy TerraPower's Natrium The world is moving to a new type of nuclear reactor: SMR Pom. i) = Modular, smaller size (50 MWe to 300 MWe) reactors allowing greater flexibility — in deployment —/ + Designed for production-line manufacturing rather t
Slide 29: HALEU Supply Issue
HALEU Supply Issue Looming for SMR Reality = Current commercial LWRs use low-enriched uranium (LEU) which has less than 5% 285U content. + Many SMRs and advanced reactors will require High ‘Assay Low Enriched Uranium (HALEU) with 25U enrichment up to 19.75%. * Currently, there is no commercial sourc
Slide 30: Data Sources
Data Sources Wang, Yitel t o Producton Review ot Acer Sane Medal loops Mcecdes (ase Swzran) wh 27,16 294 19 Au, 202, do 10.36Rheeeden15204, BL 2aov ta Promten of medcalradonudiesn Fuss: Su and urea evo” Appa Raat of nda, ene, February 201, hp ef. 106) spain 2013. 1.025, eco NP, Meck, Tuer Reson fGau